CXCL13 in laboratory diagnosis of Lyme neuroborreliosis-the performance of the recomBead and ReaScan CXCL13 assays in human cerebrospinal fluid samplesShow others and affiliations
2022 (English)In: European Journal of Clinical Microbiology and Infectious Diseases, ISSN 0934-9723, E-ISSN 1435-4373, Vol. 41, no 1, p. 175-179Article in journal (Refereed) Published
Abstract [en]
The chemokine CXCL13 is used as complement to serology in the diagnostics of Lyme neuroborreliosis (LNB). We evaluated and compared the semi-quantitative, cassette-based ReaScan CXCL13 assay with the quantitative recomBead CXCL13 assay using a collection of 209 cerebrospinal fluid samples. The categorical agreement between results interpreted as negative, grey zone, and positive by the two methods was 87%. The diagnostic sensitivity was higher using the recomBead assay, whereas specificity was higher using ReaScan. Few manual steps, and a short turn-around time with no batching of samples makes the ReaScan CXCL13 assay an attractive complement to serology in the diagnostics of LNB.
Place, publisher, year, edition, pages
Springer , 2022. Vol. 41, no 1, p. 175-179
Keywords [en]
Lyme neuroborreliosis; Diagnostics; CXCL13; ReaScan; recomBead
National Category
Microbiology in the medical area
Identifiers
URN: urn:nbn:se:liu:diva-180499DOI: 10.1007/s10096-021-04350-yISI: 000705823200001PubMedID: 34626256OAI: oai:DiVA.org:liu-180499DiVA, id: diva2:1605671
Note
Funding Agencies|European Union through the European Regional Development FundEuropean Commission; Interreg North Sea Region Programme [J-No: 38-2-7-19]
2021-10-252021-10-252023-05-04